By Chris Hutching
Friday 21st March 2003
|Text too small?|
"Most stock valuations currently aren't out of whack and there's a greater than even chance that the biotech dealmaking engine might splutter back to life with a vengeance," he told the Commercialising Biotechnology Conference in Auckland this week.
"What we can reasonably expect is a wave of mergers and acquisitions to strengthen investor confidence in the sector," he said.
"Just in case some of you big spenders out there would like to take your wallets out and spend up large, some of the once-hot names now trading below cash value include Celera Genomics, Transkaryotic Therapies, Incyte Genomics, Sequenom and Curagen.
"Indeed, there was much market speculation only a couple of weeks ago when Wrightson snared just over 15% of Genesis at much below Genesis' cash value if the company was wound up today.
But the biggest recent news was the impending merger of Pfizer and Pharmacia Corp. "It effectively creates a new model for US drug companies."
No comments yet
NZ dollar becalmed on US-China trade/politics nexus
Govt to pull Infrastructure Commission into Auckland port imbroglio
Wind to displace diesel for Stewart Island power
Eroad's five year target: doubling unit sales
Blinky boxes and gobbledegook: tips for choosing a cyber-security vendor
Govt support for NZME/Stuff merger difficult, not impossible, says Jarden
NZ dollar stalled; US-China trade signals remain mixed
Ryman warns NZ, Australia to take population ageing more seriously
MARKET CLOSE: NZ shares fall as US-China trade concerns weigh on markets; Ryman slips
NZ dollar stalled; US-China trade deal may be postponed